Global Antihypertensive Drugs Market Expected to Reach $28 Billion by 2026

According to a new report published by Allied Market Research, titled, "Antihypertensive Drugs Market by Therapeutic Class and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2019–2026," the global antihypertensive drugs market was valued at $22 billion in 2018, and is expected to reach $28 billion by 2026, registering a CAGR of 3.1% from 2019 to 2026. 

Hypertension is a long-term medical condition, which is marked by the rise in blood pressure. Blood pressure is considered higher than normal when the systolic blood pressure is more than 140mm Hg or the diastolic blood pressure is more than 90 mm Hg. Moreover, this medical condition is accompanied with other complications such as dementia, heart failure, and kidney diseases. Therefore, this condition requires an early diagnosis and treatment. The drugs employed in the treatment of this condition are termed as antihypertensive. Different type of the antihypertensive drugs available in the market include calcium channel blockers and vasodilators. 

The factors that significantly contribute toward the growth of the global antihypertensive drugs market include surge in incidence of hypertension across the globe. Furthermore, rise in awareness related to complications associated with hypertension acts as a major factor that fuels the growth of the market. Moreover, increase in geriatric population and sedentary lifestyle boost the growth of the market. However, recent patent expirations hinder the growth of the antihypertensive drugs market. On the contrary, surge in research related to antihypertensive drugs is expected to offer lucrative opportunities during the forecast period.

The global antihypertensive drugs market is studied on the basis of therapeutic class, distribution channel, and region to provide a detailed assessment of the market. Depending on therapeutic class, the market is divided into diuretics, ACE inhibitors, calcium channel blockers, vasodilators, beta-adrenergic blockers, and others. By distribution channel, it is categorized into retail pharmacy, hospital pharmacy, and e-commerce. Region wise, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA). According to therapeutic class, the calcium channel blockers segment occupied the largest share in 2018, owing to lesser side effects exhibited by these drugs as compared to the other type of antihypertensive drugs. However, the ACE inhibitors segment is expected to grow at the fastest rate during the forecast period, due to benefits offered such as positive impact on overall health and decrease in progression of kidney diseases.

By distribution channel, the hospitals segment occupied the largest share, due to rise in number of hospitals worldwide. Furthermore, antihypertensive drugs are prescription-based medications, which are mostly prescribed by the specialized healthcare professionals available in hospitals, thereby propelling the growth of this segment. Conversely, the e-commerce segment is expected to exhibit the fastest growth rate during the forecast period, owing to surge in the use of internet across the globe.

In 2018, North America accounted for the major share in the antihypertensive drugs market, owing to easy availability of these drugs. Moreover, surge in incidence of hypertension and rise in geriatric population act as the key drivers of the market in this region. However, Asia-Pacific is projected to register the fastest growth during the forecast period, owing to surge in awareness related to the use of antihypertensive drugs. Furthermore, surge in research related to antihypertensive drugs in developing economies is anticipated to offer lucrative opportunities for antihypertensive providers to expand their business. In addition, the constantly evolving life science industry drives the growth of the market in the developing economies such as India and China.

Key Findings of the Study:

• Calcium channel blockers occupied one-fourths share of the global antihypertensive drugs market in 2018.
• The ACE inhibitors segment is anticipated to grow with the highest CAGR throughout the forecast period.
• The vasodilators accounted for more than one-fifths share of the market in 2018.
• Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA.